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Background: Though herbal medicines have been used for cancer prevention and treatment, their scientific evidences
still remain unclear so far. Thus, complementary and alternative medicine (CAM) project has been actively executed to
reveal the scientific evidences in the USA and other countries. In the present study, we elucidated antitumor mechanism
of Chijongdan, an oriental prescription of Rhus verniciflua, processed Panax ginseng, Persicaria tinctoria and Realgar, that
has been traditionally applied for cancer treatment in Korea.
Methods: Chijongdan was prepared with extracts of Rhus verniciflua, processed Panax ginseng, Persicaria tinctoria and
processed Realgar. The cytotoxicity of Chijongdan was measured by MTT colorimetric assay. Cell cycle analysis was
performed by FACS. Western blot was performed to see the apoptosis related proteins.
Results: Chijongdan significantly exerted cytotoxicity in A549, H460 and H1299 non-small cell lung carcinoma (NSCLC)
cells by MTT assay and also increased the number of ethidium homodimer positively stained cells in A549 NSCLC cells.
Also, cell cycle analysis showed that Chijongdan increased sub-G1 population in a concentration dependent manner in
A549 cells. In addition, Western blotting revealed that Chijongdan activated cleaved PARP, and caspase 9/3,
while attenuated the expression of survival genes such as Bcl-2, Bcl-XL and survivin in A549 cells. Furthermore,
Chijongdan suppressed the expression of ribosomal biogenesis related proteins such as upstream binding
factor (UBF), Fibrillarin, NPM (B23) and Importin-7 (IPO7) and conversely pan-caspase inhibitor Z–VAD-FMK
reversed the apoptotic ability of Chijongdan to cleave PARP and caspase 3 and attenuate the expression of
UBF and Fibrillarin in A549 cells.
Conclusions: These findings suggest that Chijongdan induces apoptosis and inhibits ribosomal biogenesis
proteins via caspase activation.
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Though several therapeutic approaches such as surgery,
chemotherapy, and radiotherapy have been effectively
applied for cancer therapy, cancer is still one of intract-
able diseases all over the world [1,2]. Apoptosis, so
called programmed cell death (PCD), is characterized by
specific morphological features of cell shrinkage, nuclear
condensation and fragmentation and membrane blebbing
in the cells [3]. It usually includes two classical apoptotic* Correspondence: sungkim7@khu.ac.kr
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unless otherwise stated.pathways such as the extrinsic death receptor pathway
and intrinsic mitochondrial pathway. The extrinsic path-
way is triggered by plasma membrane death receptor with
its extracellular ligand Fas-L to activate caspase 8/3, while
intrinsic pathway releases cytochrome c to form apopto-
some to activate caspase 9/3 in the cells [4]. Thus, recently
apoptosis is one of important targets in cancer therapy
[4,5] and also some herbal medicines are attractive for
cancer prevention and therapy with little toxicity or com-
bination supplement with anticancer agents [6-8].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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in the cytoplasm and nucleolus to coordinate the synthesis
and processing of rRNAs, and make the assembly of those
rRNAs with the ribosomal proteins to maintain cell
homeostasis and survival [9]. Also, there are accumulating
evidences that altered ribosomal proteins [10,11] and nu-
clear proteins [12-14] such as Twist, upstream binding
factor (UBF), Fibrillarin, nucleophosmin (NPM, B23),
exportin1 (XPO1) and importin7 (IPO7) are involved in
cancer progression [15]. In contrast, some ribosomal
proteins such as L13a, rp22 and rp23 were reported to
function as cell cycle checkpoints and compose a new
family of cell proliferation regulators [9].
Chijongdan, consisting of Rhus verniciflua, processed
Panax ginseng, Persicaria tinctoria and Realgar, has been
traditionally applied for cancer treatment in Korea. Never-
theless, the scientific evidence of Chijongdan is still lack-
ing except one clinical case report [16] that Chijongdan
retarded tumor size of the patient with colorectal cancer
without side effect until now. Thus, in the present study,
the underlying antitumor mechanism of Chijongdan using
minimum dose (1%) of Realgar to reduce its toxicity and
enhance synergistic antitumor activity with other constitu-
ent herbs was elucidated in association with apoptosis




Chijongdan, consisting of three herbs and one mineral
such as Rhus verniciflua, processed Panax ginseng, Persi-
caria tinctoria and processed Realgar, was prepared in 95%
ethanol. Briefly, three herbs and one mineral were obtained
from Korean Medical Hospital of Kyunghee University
(Seoul, Korea) and kindly authenticated by Dr. Nam-In
Baek (Department of Oriental Herbal Materials, Kyunghee
University). Its four constituents (Rhus verniciflua, Panax
ginseng, Persicaria tinctoria and processed Realgar), which
were stored at Cancer Prevention Material Development
Research Center (CPMDRC, Korea), and soaked with etha-
nol (2 liters × 3 changes) at room temperature for 7 days.
The extract was filtered through filter paper (pore size,
3 μm), evaporated (Rotary Evaporator, model NE-1,
Japan), and lyophilized (Freeze Dryer, Lioalfa-6, Telstar,
Terrassa, Spain) to produce dry powder. Then, the ex-
tracts of Chijongdan were mixed together with the ratio
of Chijongdan constituents (Rhus verniciflua, Panax
ginseng, Persicaria tinctoria, Realgar = 60:30:9:1%).
Cell culture
A549, H460, and H1299 cells were obtained from
American Type Culture Collection (ATCC). The cells
were cultured in RPMI 1640 (Welgene, Daegu, Korea)
supplemented with 10% fetal bovine serum (FBS) (Welgene,Daegu, Korea) and 1% antibiotics at 37°C in a humidified
5% CO2 atmosphere.
Cytotoxicity assay
The cytotoxicity of Chijongdan and its four constitu-
ents was measured in A549, H460 and H1299 lung
adenocarcinoma cells by MTT colorimetric assay. The
cells were seeded onto 96-well microplates at a density
of 1 × 104 cells per well and treated with various con-
centrations of Chijongdan, Rhus verniciflua, processed
Panax ginseng, Persicaria tinctoria and Realgar for
24 ~ 48 h. MTT working solution (5 mg/ml in PBS)
was added to each well and incubated at 37°C for 2 h.
The optical density (OD) was then measured at
570 nm using a microplate reader (Sunrise, TECAN,
Männedorf, Switzerland). Cell viability was calculated
as a percentage of viable cells in Chijongdan, Rhus
verniciflua, processed Panax ginseng, Persicaria tinc-
toria and Realgar-treated group versus untreated con-
trol by the following equation.
Cell viability %ð Þ ¼ ½OD Chijongdan or each constituentð Þ
‐ OD Blankð Þ=½OD Controlð Þ
‐ OD Blankð Þ  100:
Ethidium homodimer assay
To measure cell death, we used DAPI and ethidium
homodimer dye following the manufactures’ instruc-
tions (Molecular Probes). In brief, A549 cells were
treated with 100 and 200 μg/ml of Chijongdan for
24 h. After incubation, cells were fixed in 4% methanol-
free formaldehyde solution, stained with the 5 μM eth-
idium homodimer and then incubated at 37°C for 30 min
in the dark. Then the cells were mounted with mounting
medium containing DAPI and then visualized under a
Fluoview FV10i confocal microscope (OLYMPUS, Tokyo,
Japan).
Cell cycle analysis
A549 cells treated with Chijongdan (50, 100, 200 and
400 μg/ml) for 24 h were fixed in 75% ethanol at −20°C,
resuspended in PBS containing RNase A (1 mg/ml), and
incubated for 1 h at 37°C. The fixed cells were stained
with propidium iodide (50 μg/ml) for 30 min at room
temperature in dark. The DNA contents of the stained
cells were analyzed using CellQuest Software with the
FACSCalibur flow cytometry (Becton Dickinson, Franklin
Lakes, NJ).
Western blotting
Whole cell lysates from the cells exposed to Chijongdan
(25, 50, 100 and 200 μg/ml) for 24 h were prepared
using RIPA buffer (50 mM Tris–HCl, pH 7.5, 150 mM
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EDTA, 0.5% sodium deoxycholate). The protein con-
tents in the supernatants were measured by using a
Bio-Rad DC protein assay kit II (Bio-Rad, Hercules,
CA), separated on 4–12% NuPAGE Bis-Tris gels (Invi-
trogen, Carlsbad, CA) and electro-transferred onto aFigure 1 Cytotoxicity of Chijongdan and its constituents in non-small
to Chijongdan for 24 or 48 h. Then MTT assay was performed as shown in
A549 (A), H460 (B), H1299 (C) and RAW264.7 cells (D). All data were expresHybond ECL transfer membrane (GE Health Are Bio-
Science, Piscataway, NJ). The membranes were blocked
with 5% nonfat dry milk and immunoblotted with
caspase-3, caspase-9, PARP, Bcl-2, Bcl-xL, survivin, UBF,
Fibrillarin, NPM (B23), IPO7 or β-actin (Cell signaling,
Danvers, MA) antibodies.cell lung carcinoma cells. A549, H460 and H1299 cells were exposed
Methods. Effect of Chijongdan and the constituents on cytotoxicity in
sed as means ± standard deviation (SD).
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Statistical analysis of the data was conducted using
Sigmaplot version 12 software (Systat Software Inc., San
Jose, CA). All data were expressed as means ± standard de-
viation (SD). One-way ANOVA was used for comparison
of multiple groups. Student t-test was used for comparison
of two groups. Statistical difference was set at p values
of <0.05 between control and Chijongdan-treated groups.
Results
Chijongdan and its constituents exerted the cytotoxicity
against human non-small cell lung cancer cells
To evaluate the cytotoxic effect of Chijongdan and its con-
stituents in human non-small cell lung carcinoma cells
(NSCLC), we conducted MTT assay. A549, H460 and
H1299 cells were treated with various concentrations (0,
6.25, 12.5, 25, 50, 100 or 200 μg/ml) of Chijongdan and its
constituents such as Rhus verniciflua, processed PanaxFigure 2 Effect of Chijongdan on ethidium homodimer stained cells i
50, 100 and 200 μg/ml of Chijongdan for 24 h. (A) Morphology of A549 ce
with DAPI and ethidium homodimer dyes, mounted with mounting mediu
confocal microscope (OLYMPUS, Tokyo, Japan).ginseng, Persicaria tinctoria and processed Realgar for
24 h and 48 h. Chijongdan significantly decreased the via-
bility of A549, H460 and H1299 cells (Figure 1A, B, C).
However, the cytotoxicity of Chijongdan was weaker in
RAW264.7 macrophage cells compared to H1299 cells
(Figure 1D), but not significantly for other NSCLCs,
implying somewhat cytotoxicity in normal cells. Realgar
was more cytotoxic in A549 cells than other constituent
herbs such as Rhus verniciflua, processed Panax ginseng
and Persicaria tinctoria (Figure 1A).Chijongdan induced apoptotic morphology in A549 cells
Morphological changes in Chijongdan treated A549 cells
were observed under inverted microscopy. As shown in
Figure 2 A, the cells treated with 0, 50, 100 or 200 μg/ml
of Chijongdan for 24 h exhibited apoptotic features such
as apoptotic bodies and cell shrinkage.n A549 cells. A549 cells were treated with various concentrations of
lls was observed in inverted microscope. (B) A549 cells were stained
m containing DAPI and then visualized under a Fluoview FV10i
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stained cells in A549 cells
Ethidium homodimer dye staining was performed to
detect cell death. We observed apoptotic bodies inFigure 3 Effect of Chijongdan on sub G1 population in A549 cells. A5
for 24 h and stained with propidium iodide (50 μg/ml) for 30 min at room
analyzed by the FACSCalibur flow cytometry. (B) Bar graphs represent perc
standard deviation (SD). ***p < 0.001 vs. untreated control.Chijongdan treated A549 cells in a dose depen-
dent manner, indicating apoptotic feature, while in-
tact morphology was shown in untreated control
(Figure 2B).49 cells were treated with 50, 100, 200 and 400 μg/ml of Chijongdan
temperature in dark. (A) The DNA contents of the stained cells were
entages of apoptotic portion. All data were expressed as means ±
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in A549 cells
To investigate the effect of Chijongdan on cell cycle phase
distribution, A549 cells were treated with various con-
centrations (0, 50, 100, 200 or 400 μg/ml) of Chijongdan.
As shown in Figure 3A and 3B, Chijongdan significantly
increased sub-G1 phase proportion in a dose dependent
manner.Chijongdan regulated apoptosis related proteins in
A549 cells
To confirm whether the cytotoxic effect of Chijongdan
in A549 is associated with apoptosis, we performed
Western blotting. A549 cells were treated with 25, 50,
100 and 200 μg/ml of Chijongdan for 24 h. The cell ly-
sates were prepared and subjected to Western blotting
for PARP, procasepase-3, −9, Bcl-xL, Bcl-2, and survivin.
Consistent with previous data, anti-apoptotic proteins
such as Bcl-xL, Bcl-2, and survivin were downregulated
by Chijongdan in a dose dependent manner, while pro-
apoptotic protein such as caspase-3, −9 and PARP were
cleaved in A549 cells (Figure 4A,B).Figure 4 Effect of Chijongdan on pro-apoptotic and anti-apoptotic
proteins in A549 cells. A549 cells were treated with 25, 50, 100 and
200 μg/ml of Chijongdan for 24 h and Western blotting was
performed for pro-apoptotic (A) and anti-apoptotic proteins
(B) as shown in Methods.Effect of Chijongdan on apoptotic and ribosome
biogenesis related proteins was reversed by pancaspase
inhibitor Z-VAD-FMK in A549 cells
It was well demonstrated that ribosome production was
enhanced in cancer cells and that ribosome biogenesis
played a crucial role in tumor progression [17]. To
confirm that Chijongdan can regulate the ribosome
biogenesis related proteins, we conducted Western blot-
ting. As shown in Figure 5A, Chijongdan down-regulated
UBF, Fibrillarin, NPM and IPO7 in a dose dependent
fashion. Conversely, the effects of Chijongdan on ribo-
some biogenesis and apoptosis were reversed by pan-
caspase inhibitor Z–VAD-FMK (Figure 5B), indicating
that Chijongdan induces apoptosis and inhibits riboso-
mal biogenesis proteins via caspase activation.
Discussion
Lung cancer is the most common cause of cancer death
worldwide [18]. Among lung cancers, 80% are classified
as non-small cell lung cancer (NSCLC) and 20% are
small cell lung cancer (SCLC). Though recently ad-
vanced computed tomography (CT) scanning made pos-
sible detection of NSCLCs at earlier stages [19], overFigure 5 Effect of Chijongdan on apoptotic and ribosome
biogenesis related proteins was reversed by pancaspase inhibitor
Z-VAD-FMK in A549 cells. (A) Effect of Chijongdan on ribosomal
biogenesis related proteins in A549 cells. (B) Effect of pan-caspase
inhibitor Z–VAD-FMK on the ability of Chijongdan to inhibit ribosomal
biogenesis and induce apoptosis in A549 cells. A549 cells were treated
with 100 μg/ml of Chijongdan and/or pan-caspase inhibitor Z–VAD-FMK
for 24 h and Western blotting was performed for UBF, Fibrillarin and
PARP as shown in Methods.
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metastatic at the time of diagnosis [20]. Cell prolifera-
tion needs to duplicate their own structural and func-
tional components [21] via increased protein synthesis
which, in turn, followed by an up-regulation of the ribo-
some biogenesis rate [21-23].
Herbal mixture Chijongdan has been traditionally used
for cancer therapy without clear scientific evidences.
Among constituents of Chijongdan, Rhus verniciflua was
known to have antitumor activity in A549 lung cancer
[24], MCF-7 breast cancer [25], lymphoma [26], osteo-
sarcoma [27] and renal cancer [28] and also processed
Panax ginseng was reported to exert antitumor effect in
AGS gastric cancer. Also, Persicaria tinctoria contained
tyrosine kinase inhibitory compounds [29] and Realgar
was reported to be too cytotoxic and apoptotic in chronic
lymphocytic leukemia or cervical cell lines [30,31]. Here,
based on previous antitumor evidences of its constituents,
antitumor activity of Chijongdan was hypothesized. Thus,
we investigated antitumor mechanism of Chijongdan in
association with apoptosis and ribosomal proteins in non-
small lung carcinoma cells. Here we found that Chijong-
dan and its constituents significantly exerted cytotoxicity
in A549, H460 and H1299 NSCLC cells, showed morpho-
logic changes such as apoptotic bodies cell shrinkage in a
dose dependent manner and increased the number of eth-
idium homodimer positively stained cells in A549 cells,
indicating the cytotoxicity of Chijongdan was due to
apoptosis induction in A549 cells. Consistently, cell cycle
analysis showed that Chijongdan increased sub-G1 popu-
lation and also cleaved PARP, activated caspase9/3, and
attenuated the expressed of survival genes such as Bcl-2,
Bcl-xL and survivin in A549 cells, implying Chijongdan in-
duces apoptosis and suppresses survival genes. Further-
more, Chijongdan repressed the expression of ribosome
biogenesis related proteins such as UBF, Fibrillarin, NPM,
and IPO7, indicating that Chijongdan can inhibit the
rDNA transcription or processing of rRNA during cancer
progression of A549 cells. Similarly, melatonin suppressed
45S preribosomal RNA and UBF and enhanced the an-
titumor activity of puromycin in MDA-MB 231 breast
cancer cells [32]. Interestingly, the antitumor ability of
Chijongdan to cleave PARP and caspase 3 and inhibit
the expression of UBF and Fibrillarin was blocked by pan-
caspase inhibitor Z-VAD-FMK in A549 cells, demonstrat-
ing that caspase activation mediates the inhibition of
ribosomal biogenesis by Chijongdan in A549 cells.
Conclusions
Taken together, these findings suggest that Chijongdan
induces apoptosis and inhibits ribosomal biogenesis
proteins via caspase activation in A549 non-small cell
lung carcinoma cells, though it still needs further
research including in vivo efficacy and safety andpharmacodynamic studies with Chijongdan and its
constituents in the future.
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